Overview

Safety, Tolerability, PK and PD of Posiphen® in Subjects With Early Alzheimer's Disease

Status:
Recruiting
Trial end date:
2021-12-31
Target enrollment:
Participant gender:
Summary
This study evaluates the safety and pharmacological effects of 3 different doses of Posiphen® when compared to a placebo, in adult male and female patients with early Alzheimer's disease (AD).
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Annovis Bio Inc.
QR Pharma Inc.
Collaborator:
Alzheimer's Disease Cooperative Study (ADCS)
Treatments:
Phenserine
Physostigmine